Cargando…

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis

OBJECTIVE: To evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada. METHODS: A Markov model was constructed to evaluate incremental cost-utility ratios (ICUR) of 5 mg/kg and 10 mg/kg inflixim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Feng, Blackhouse, Gord, Assasi, Nazila, Gaebel, Kathryn, Robertson, Diana, Goeree, Ron
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797497/ https://www.ncbi.nlm.nih.gov/pubmed/20003364 http://dx.doi.org/10.1186/1478-7547-7-20

Ejemplares similares

Cost-Effectiveness of Catheter Ablation for Rhythm Control of Atrial Fibrillation
por: Blackhouse, Gord, et al.
Publicado: (2013)

Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis
por: Gaebel, Kathryn, et al.
Publicado: (2010)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management
por: Tsoi, Bernice, et al.
Publicado: (2015)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
por: Park, Sang Hyoung, et al.
Publicado: (2022)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
por: Lee, Yong Il, et al.
Publicado: (2021)

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
por: Savelkoul, Edo H J, et al.
Publicado: (2022)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
por: Okabayashi, Shinji, et al.
Publicado: (2017)

Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy
por: Mizoshita, Tsutomu, et al.
Publicado: (2017)

Adalimumab for refractory peripheral ulcerative keratitis
por: Cordero-Coma, Miguel, et al.
Publicado: (2012)

Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands
por: Chaudhary, Mohammad A., et al.
Publicado: (2012)

Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
por: Gagnon, Ann-Lorie, et al.
Publicado: (2021)

Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
por: Seo, Hyun Il, et al.
Publicado: (2014)

Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
por: Puthoor, Pamela R., et al.
Publicado: (2013)

Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
por: Beilman, Candace L., et al.
Publicado: (2016)

Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
por: Han, Minkyung, et al.
Publicado: (2020)

Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015)

Network meta-analysis and cost-effectiveness analysis of infliximab, cyclosporine and tacrolimus for ulcerative colitis
por: Wang, Xueqi, et al.
Publicado: (2022)

Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience
por: Yamada, Satoshi, et al.
Publicado: (2014)

Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients
por: Berends, Sophie E., et al.
Publicado: (2019)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Promising effect of infliximab on the extent of involvement in ulcerative colitis
por: Adibi, Peyman, et al.
Publicado: (2011)

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update
por: Lawlor, Garrett, et al.
Publicado: (2009)

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
por: Fasanmade, Adedigbo A., et al.
Publicado: (2009)

Pericardial Effusion due to Infliximab Therapy for Ulcerative Colitis
por: Mirza, Muhammad, et al.
Publicado: (2018)

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
por: deBruyn, Jennifer C. C., et al.
Publicado: (2021)

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
por: Schultz, Bob G, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Evaluation of adalimumab effects on left ventricle performance by echocardiography indexes among patients with immunosuppressant refractory ulcerative colitis
por: Hatamnejad, Mohammad Reza, et al.
Publicado: (2023)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
por: Armuzzi, Alessandro, et al.
Publicado: (2013)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
por: Freeman, Hugh J
Publicado: (2013)

Treatment of Recalcitrant Pyoderma Gangrenosum with Ulcerative Colitis by Adalimumab Injection
por: Lee, Jin-Hyup, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h6fe8e7pmqrkqh9hcfhk1967qv